Telix Pharmaceuticals

Telix Pharmaceuticals Forward P/E

The Forward P/E Ratio of Telix Pharmaceuticals (TLX.AX) as of Nov 20, 2026 is -417.56. In the previous year, Forward P/E Ratio was 88.32 — a change of -572.77% (lower).

Forward P/E

-417.56

YoY

-572.77%

Last updated:

Forward P/E Ratio of Telix Pharmaceuticals is 2025 -417.56 . Forward P/E Ratio of Telix Pharmaceuticals was 2024 88.32 . It decreases by -572.77% lower compared to the previous year.

The Telix Pharmaceuticals Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-215.12 USD
Jan 1, 2019
-106.76 USD
Jan 1, 2020
-66.28 USD
Jan 1, 2021
-36.95 USD
Jan 1, 2022
-44.08 USD
Jan 1, 2023
707.01 USD
Jan 1, 2024
88.32 USD
Jan 1, 2025
-417.56 USD
The Telix Pharmaceuticals Forward P/E history
YEARForward P/EYoY
-417.56-572.77%
88.32-87.51%
707.01-1,703.97%
-44.08+19.28%
-36.95-44.25%
-66.28-37.92%
-106.76-50.37%
-215.12-53.89%
-466.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Forward P/E Ratio of Telix Pharmaceuticals is -417.56 in 2025.

Forward P/E Ratio of Telix Pharmaceuticals changed from 88.32 to -417.56, representing a -572.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals